Mycophenolate mofetil in lupus nephritis

Bansal VK , Beto JA . Treatment of lupus nephritis: a meta-analysis of clinical trials . A J Kidney Dis 1997; 29: 193–199 .

Halloran P , Matthew T , Tomlanovich S , Groth C , Hooftman L , Barker C . Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomised, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Transplant Study Groups . Transplantation 1997; 63: 39–47 .

Ojo AO , Meier-Kreische HU , Hanson JA et al. Mycophenolate mofetil reduces late allograft loss independent of acute rejection . Transplantation 2000; 69: 2405–2409 .

Jayne D . Non-transplant uses of mycophenolate mofetil . Curr Opin Nephrol Hypertens 1999; 8: 563–567 .

Eugui EM , Mirkovich A , Allison AC . Lymphocyte selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholenoethyl ester (RS-61443) in rodents . Transplant Proc 1991; 23(Suppl 2): 15–18 .

Li L , Lie Z , Zhou H , Hu W . Mycophenolate mofetil showed inhibitory effect of VCAM expression during successful treatment of diffuse proliferative lupus nephritis with vascular lesions . J Am Soc Nephrol 1998; 9: 153-153 (abstract 881).

Hauser IA , Renders L , Radeke HH , Sterzel RB , Goppelt-Struebe M . Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion . Nephrol Dial Transplant 1999; 14: 58–63 .

Blaheta R , Leckel K , Wittig B et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil . Transplant Immunol 1998; 6: 251–259 .

Nowack R , Birck R , Van der Woude F . Mycophenolate mofetil for systemic vasculitis and IgA nephropathy . Lancet 1997; i(349): 774-774 .

Corna D , Morigi M , Facchinetti D et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease . Kidney Int 1997; 51: 1583–1589 .

McMurray RW , Elbourne KB , Lagoo A et al. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZBNZW F1 mouse model of systemic lupus erythematosus . J Rheumatol 1998; 25: 2364–2370 .

Jonsson CA , Erlandsson M , Svensson L et al. Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice . Cell Immunol 1999; 197: 136–144 .

Van Bruggen MC , Walgreen B , Rijke TP et al. Attenuation of murine lupus nephritis by mycophenolate mofetil . J Am Soc Nephrol 1998; 9: 1407–1415 .

Badid C , Vincent M , McGregor B et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney . Kidney Int 2000; 58: 51–61 .

Fujihara CK , Malheiros DM , Zatz R , Noronha ID . Mycophenolate mofetil attenuates renal injury in the rat remnant kidney . Kidney Int 1998; 54: 1510–1519 .

Li L , Hu W , Zhou H , Liu Z . Clinico-pathological evaluation of mycophenolate mofetil (MMF) therapy in twenty three cases of diffuse proliferative lupus nephritis (SLE-DPGN) . J Am Soc Nephrol 1999; 10: 172-172 (abstract 881).

Pashinian N , Wallace DJ , Klinenberg JR . Mycophenolate mofetil for systemic lupus erythematosus . Arthritis Rheum 1998; Suppl 41: S110-S110 (abstract 464).

Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol 1999; 10: 833–839 .

Glicklich D , Acharya A . Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide . Am J Kidney Dis 1998; 32: 318–322 .

Gaubitz M , Schorat A , Schotte H , Kern P , Domschke W . Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial . Lupus 1999; 8: 731–736 .

Briggs WA , Choi MJ , Scheel PJ Jr , Kiberd B , MacDonald A . Successful mycophenolate mofetil treatment of glomerular disease . Am J Kidney Dis 1998; 31: 213–217 .

Chen Y , Lu F , Li A , Chen W , Zou W . Mycophenolate mofetil combined with corticosteroid to treat IV lupus nephritis . J Am Soc Nephrol 1999; 10: 98-98 (abstract 502).

Kingdon E , Mclean A , Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. (Submitted for publication).

Conteras G , Roth D , Berho M , Perez G , Gomez E , Acosta M . Immunosuppressive therapy for proliferative lupus nephritis: preliminary report of a prospective randomised clinical trial with mycophenolate mofetil . J Am Soc Nephrol 1999; 10: 99-99 (abstract 507).

Petri M . Mycophenolate mofetil treatment of systemic lupus erythematosus . Arthritis Rheum 1999; Suppl 42: S303-S303 (abstract 1395).

Epinette WW , Parker CM , Jones EL , Greist MC . Mycophenolic acid for psoriasis: a review of pharmacology, long term efficacy and safety . J Am Acad Dermatol 1987; 17: 962–971 .

Roche. Cellcept package insert. 1998.

Chan MT , Li FK , Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis . New Engl J Med 2000; 343: 1156–1162 .